Trials / Withdrawn
WithdrawnNCT00404157
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g
A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III, multicenter, extension study to evaluate the safety of rituximab administered on a scheduled basis approximately every 6 months. All subjects who complete their Week 52 visit in Study U2970g will be eligible for this study, as long as the inclusion and exclusion criteria are met.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab |
Timeline
- First posted
- 2006-11-27
- Last updated
- 2017-04-12
Source: ClinicalTrials.gov record NCT00404157. Inclusion in this directory is not an endorsement.